Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRVNASDAQ:BYSINASDAQ:CTORNASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.18-4.8%$1.36$1.05▼$10.16$36.99M1.56254,280 shs251,221 shsBYSIBeyondSpring$3.17+1.9%$1.88$0.98▼$3.44$127.81M0.0731,903 shs1.34 million shsCTORCitius Oncology$2.63+69.7%$0.98$0.55▼$4.42$188.18M-0.071.17 million shs20.57 million shsSLGLSol-Gel Technologies$7.43+4.1%$7.12$3.34▼$16.50$20.73M1.133,010 shs15,145 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics0.00%-1.67%+0.85%-78.97%-82.15%BYSIBeyondSpring0.00%+13.62%+83.34%+104.52%+25.30%CTORCitius Oncology0.00%+78.91%+189.01%+270.42%+262,999,900.00%SLGLSol-Gel Technologies0.00%-1.20%-2.11%+30.26%-10.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics3.6381 of 5 stars4.55.00.00.00.62.50.6BYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/ACTORCitius Oncology0.3858 of 5 stars2.00.00.00.00.01.70.0SLGLSol-Gel Technologies2.554 of 5 stars3.55.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$17.711,401.21% UpsideBYSIBeyondSpring 0.00N/AN/AN/ACTORCitius Oncology 2.00Hold$3.0014.07% UpsideSLGLSol-Gel Technologies 3.00Buy$40.00438.36% UpsideCurrent Analyst Ratings BreakdownLatest SLGL, CTOR, BYSI, and ACRV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025ACRVAcrivon TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/15/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/5/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.005/4/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/26/2025ACRVAcrivon TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/26/2025ACRVAcrivon TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ABYSIBeyondSpring$1.75M73.04N/AN/A($0.37) per share-8.57CTORCitius OncologyN/AN/AN/AN/A$0.64 per shareN/ASLGLSol-Gel Technologies$11.54M1.80N/AN/A$10.36 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.22N/AN/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)BYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/ACTORCitius OncologyN/AN/A0.00∞N/AN/A-53.88%-18.86%N/ASLGLSol-Gel Technologies-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/14/2025 (Estimated)Latest SLGL, CTOR, BYSI, and ACRV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/23/2025Q1 2025SLGLSol-Gel TechnologiesN/A-$3.20N/A-$3.20N/A$1.03 million5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/13/2025Q1 2025ACRVAcrivon Therapeutics-$0.57-$0.51+$0.06-$0.51N/AN/A5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A3/27/2025Q4 2024ACRVAcrivon Therapeutics-$0.69-$0.60+$0.09-$0.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A11.1711.17BYSIBeyondSpringN/A2.492.49CTORCitius Oncology0.110.360.05SLGLSol-Gel TechnologiesN/A5.125.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%BYSIBeyondSpring40.29%CTORCitius Oncology70.52%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%BYSIBeyondSpring29.31%CTORCitius Oncology4.57%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.35 million28.69 millionNot OptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableCTORCitius OncologyN/A71.55 million68.28 millionN/ASLGLSol-Gel Technologies502.79 million933,000OptionableSLGL, CTOR, BYSI, and ACRV HeadlinesRecent News About These CompaniesSol-Gel Technologies LtdJune 21 at 5:15 PM | morningstar.comSol Gel Tech Stock Price HistoryJune 1, 2025 | investing.comSol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | finanznachrichten.deSol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays PessimisticMay 23, 2025 | msn.comSol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D ExpensesMay 23, 2025 | quiverquant.comSol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | globenewswire.comInsider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of SharesMay 3, 2025 | uk.finance.yahoo.comThis Sol-Gel Technologies Insider Increased Their Holding In The Last YearMay 2, 2025 | finance.yahoo.comSol-Gel Announces Reverse Share SplitMay 1, 2025 | globenewswire.comSol-Gel, Mayne Pharma enter product purchase agreementApril 17, 2025 | markets.businessinsider.comSol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.April 17, 2025 | finanznachrichten.deSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.April 17, 2025 | globenewswire.comGlobal Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth AnalysisApril 7, 2025 | globenewswire.comSol-Gel Technologies Approves Reverse Share Split and Compensation Policy RenewalApril 1, 2025 | tipranks.comSLGL Gears Up to Report Q4 Earnings: Here's What You Should KnowFebruary 25, 2025 | zacks.comIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?February 7, 2025 | finance.yahoo.comSol Gel Technologies Ltd (SLGL) Stock Trading RecapDecember 26, 2024 | bovnews.comIs SolGel Technologies (SLGL) a Great Value Stock Right Now?December 25, 2024 | zacks.comSol-Gel Technologies Reports Strong Q3 2024 ResultsNovember 21, 2024 | markets.businessinsider.comSol-Gel announces 180-day extension to regain compliance with NasdaqNovember 21, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong Recoveries3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking StocksSLGL, CTOR, BYSI, and ACRV Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.18 -0.06 (-4.84%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.22 +0.04 (+3.39%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.BeyondSpring NASDAQ:BYSI$3.17 +0.06 (+1.93%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.36 +0.19 (+5.96%) As of 06/20/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Citius Oncology NASDAQ:CTOR$2.63 +1.08 (+69.68%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.22 -0.42 (-15.78%) As of 06/20/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Sol-Gel Technologies NASDAQ:SLGL$7.43 +0.29 (+4.06%) Closing price 06/20/2025 03:57 PM EasternExtended Trading$7.36 -0.07 (-1.01%) As of 06/20/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
